The BEST-BE observational study will track 1,000 bronchiectasis patients to measure the impact of brensocatib on pulmonary exacerbations and patient quality of life.
RT’s Three Key Takeaways: Real-World Evidence: The BEST-BE study will monitor 1,000 adults with non-cystic fibrosis bronchiectasis over two years to evaluate the effectiven...
RT’s Three Key Takeaways: Real-World Evidence: The BEST-BE study will monitor 1,000 adults with non-cystic fibrosis bronchiectasis over two years to evaluate the effectiven...